|Articles|January 18, 2002
CDER Drug Information, Updated 12/27/01
Author(s)BioPharm International Editors
New and Generic Drug Approvals [Includes Drug Label and Approval Letter] (Updated 12/27/2001)
Advertisement
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
FDA Clears In-Vivo Gene Editing Therapy PBGENE-DMD for Duchenne Trial
2
European Commission Approves Uplizna as Add-On Therapy for Antibody-Positive Generalized Myasthenia Gravis
3
Preclinical Study Finds Subcutaneous Nanotrastuzumab Comparable to Herceptin HYLECTA in Minipig Model
4
The Clinical Execution Gap: Why Great Science Often Fails at the Trial Stage
5